Biochemists discover new strategy to combat pediatric bone cancer
A LINGO‑1‑targeted antibody‑drug conjugate (opicinumab‑MMAE) suppresses Ewing sarcoma tumor growth in preclinical models, offering a promising, less toxic therapeutic strategy.
Researchers at the UNC School of Medicine and UNC Lineberger Comprehensive Cancer Center identified LINGO‑1 as a surface protein expressed on Ewing sarcoma cells and developed a novel antibody‑drug conjugate (opicinumab‑MMAE) that directs cytotoxic agents to these cells. In immunocompromised preclinical models, the ADC suppressed tumor growth without overt toxicity, suggesting it may improve outcomes for patients with this aggressive, rare pediatric bone cancer.
We hope these findings will pave the way for the development of more effective targeted therapies and ultimately improve outcomes for patients with this devastating disease.
Evidence level: Állatkísérletes. Állatmodellben vizsgálták.
Related signals
- Revisiting CDKN2A dysregulation in Ewing sarcoma
- Emerging therapies in Ewing sarcoma
- Genome‑wide association study meta‑analysis identifies susceptibility loci informing Ewing sarcoma etiology and potential mechanisms of risk
- Integrated Immunotherapy Target Atlas for Ewing Sarcoma
- Rewiring the fusion oncoprotein EWSR1::FLI1 in Ewing sarcoma with bivalent small molecules